ORIGINAL PAPER
Indications, response, and side effects of biologic treatment in Behçet’s disease: an 8-year study with follow-up
1
Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Iran
2
Department of Neurology, Shiraz University of Medical Sciences, Iran
Submission date: 2023-07-05
Final revision date: 2023-11-19
Acceptance date: 2024-01-30
Online publication date: 2024-04-05
Corresponding author
Saeedeh Shenavandeh
Division of Rheumatology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, PO Box: 71345-1414, e-mail: shenavande@sums.ac.ir
Division of Rheumatology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, PO Box: 71345-1414, e-mail: shenavande@sums.ac.ir
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The treatment of Behçet’s disease has improved significantly with the introduction of biologic therapies. However, there is still a need for more information about their use. This study aimed to evaluate the indications, response, and side effects of biologic agents in patients with refractory or severe Behçet’s disease in the south of Iran, their follow-up and reasons for changing the biologics.
Material and methods:
A retrospective analysis was conducted on 44 patients aged 16–65 years who were prescribed biologic agents for at least 6 months. The clinical history, partial and complete remission at 6 and 12 months, occurrence of side effects, and need for switching to a second or third biologic agent were recorded.
Results:
The most common indications for starting biologic agents were ophthalmic (68.2%), parenchymal brain involvement (15.9%), and arthritis (11.4%). Improvement was observed in various manifestations of Behçet’s disease, with complete remission in 86, 51.6, 92.8, 66.7, 42.9, 33.3, and 80.0% of oral aphthous lesions, ophthalmic activity, genital aphthous lesions, skin activity, arthritis, brain parenchymal lesions, and vascular activity, respectively, 6 months after starting biologic agents. These rates were unchanged or increased at the 12-month follow-up. In 25.0% of patients, a switch to a second biologic agent was necessary due to severe disease, side effects, or refractory disease. Side effects occurred in 16.3% and 33.3% of patients on the first and second biologic agents, respectively. The majority of side effects were not serious.
Conclusions:
We found a promising improvement at 6-month and 12-month follow-ups with various biologic agents in treating Behçet’s disease with an acceptable safety profile.
The treatment of Behçet’s disease has improved significantly with the introduction of biologic therapies. However, there is still a need for more information about their use. This study aimed to evaluate the indications, response, and side effects of biologic agents in patients with refractory or severe Behçet’s disease in the south of Iran, their follow-up and reasons for changing the biologics.
Material and methods:
A retrospective analysis was conducted on 44 patients aged 16–65 years who were prescribed biologic agents for at least 6 months. The clinical history, partial and complete remission at 6 and 12 months, occurrence of side effects, and need for switching to a second or third biologic agent were recorded.
Results:
The most common indications for starting biologic agents were ophthalmic (68.2%), parenchymal brain involvement (15.9%), and arthritis (11.4%). Improvement was observed in various manifestations of Behçet’s disease, with complete remission in 86, 51.6, 92.8, 66.7, 42.9, 33.3, and 80.0% of oral aphthous lesions, ophthalmic activity, genital aphthous lesions, skin activity, arthritis, brain parenchymal lesions, and vascular activity, respectively, 6 months after starting biologic agents. These rates were unchanged or increased at the 12-month follow-up. In 25.0% of patients, a switch to a second biologic agent was necessary due to severe disease, side effects, or refractory disease. Side effects occurred in 16.3% and 33.3% of patients on the first and second biologic agents, respectively. The majority of side effects were not serious.
Conclusions:
We found a promising improvement at 6-month and 12-month follow-ups with various biologic agents in treating Behçet’s disease with an acceptable safety profile.
REFERENCES (30)
2.
Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 2015; 62: 67–74, DOI: 10.1016/j.jaut.2015.06.005.
3.
Desbois AC, Vallet H, Domont F, et al. Management of severe complications in Behcet’s disease with TNF inhibitors. Expert Opin Biol Ther 2017; 17: 853–859, DOI: 10.1080/ 14712598.2017.1328496.
4.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol 2018; 14: 107–119, DOI: 10.1038/nrrheum.2017.208.
5.
Uke P, Gorodkin R, Beare N. Biologic therapy for Behçet’s uveitis: a systematic review. Br J Ophthalmol 2020; 104: 1045–1051, DOI: 10.1136/bjophthalmol-2019-314154.
6.
Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785–796.e3, DOI: 10.1016/j.ophtha. 2013.09.048.
7.
Sota J, Rigante D, Lopalco G, et al. Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int 2018; 38: 25–35, DOI: 10.1007/s00296-017-3775-5.
8.
Kidd DP. Rituximab is effective in severe treatment-resistant neurological Behçet’s syndrome. J Neurol 2015; 262: 2676–2677, DOI: 10.1007/s00415-015-7897-y.
9.
Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol 2008; 18: 306–308, DOI: 10.1007/s10165-008-0057-9.
10.
Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in in- tractable ocular lesions of Behcet’s disease; randomized single- blind control study (pilot study). Int J Rheum Dis 2010; 13: 246–252, DOI: 10.1111/j.1756-185X.2010.01546.x.
11.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Crite- ria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338–347, DOI: 10.1111/jdv.12107.
12.
Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728–733, DOI: 10.1093/rheumatology/38.8.728.
13.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61–70, DOI: 10.1016/j.semarthrit. 2010.09.002.
14.
Horiguchi N, Kamoi K, Horie S, et al. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome. Sci Rep 2020; 10: 22227, DOI: 10.1038/s41598-020-78718-z.
15.
Adeeb F, Ng WL, Khan MU, et al. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease. Eur J Rheumatol 2017; 4: 254–259, DOI: 10.5152/eurjrheum.2017.17046.
16.
Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 2017; 36: 183–189, DOI: 10.1007/s10067-016-3480-x.
17.
Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012; 6: 5–12, DOI: 10.2147/BTT.S27343.
18.
Mesquida M, Molins B, Llorenç V, et al. Current and future treatments for Behçet’s uveitis: road to remission. Int Ophthalmol 2014; 34: 365–381, DOI: 10.1007/s10792-013-9788-5.
19.
Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet’s disease: a systematic literature review. Semin Arthritis Rheum 2020; 50: 797–804, DOI: 10.1016/j.semarthrit. 2020.05.017.
20.
Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behçet’s disease using infliximab. Clin Exp Rheumatol 2011; 29 (4 Suppl 67): S58–S63.
21.
Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol 2019; 71: 2081–2089, DOI: 10.1002/art.41026.
22.
Fabiani C, Vitale A, Emmi G, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol 2019; 38: 63–70, DOI: 10.1007/s10067-018-4069-3.
23.
Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011; 29 (4 Suppl 67): S54–S57.
24.
Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford) 2012; 51: 1825–1831, DOI: 10.1093/ rheumatology/kes130.
25.
Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet’s disease. Ocul Immunol Inflamm 2012; 20: 198–202, DOI: 10.3109/09273948.2012.670360.
26.
Zlatanović G, Jovanović S, Veselinović D, Zivković M. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet’s disease and HLA B51 positive vasculitis]. Vojnosanit Pregl 2012; 69: 168–174, DOI: 10.2298/vsp1202168z [Article in Serbian].
27.
Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 2013; 31: 320–321.
28.
Cordero-Coma M, Salom D, Díaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology 2011; 118: 1892.e3-4, DOI: 10.1016/ j.ophtha.2011.05.019.
29.
Calvo-Río V, de la Hera D, Blanco R, et al. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 2014; 32: 864–868.
30.
Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large- scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther 2019; 21: 2, DOI: 10.1186/s13075-018-1793-7.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
